Lantheus stock is trading -32.93% below its average target price of $134.69 after dropping -8.1% during today's afternoon session. Analysts are giving the Mid-Cap Biotechnology company an average rating of buy and target prices ranging from $110.0 to $166.0 per share.
Lantheus has an elevated short interest of 11.7%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 7.37. Only 2.5% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. 107.5% of Lantheus shares are held by institutional investors, which indicates a high level of confidence in the stock.
Institutions Invested in Lantheus
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Blackrock Inc. | 12% | 8,536,815 | $771,215,835 |
| 2024-09-30 | Vanguard Group Inc | 11% | 7,420,009 | $670,323,585 |
| 2024-09-30 | Janus Henderson Group PLC | 5% | 3,588,571 | $324,191,490 |
| 2024-09-30 | Farallon Capital Management LLC | 4% | 2,955,227 | $266,975,196 |
| 2024-09-30 | State Street Corporation | 4% | 2,518,886 | $227,556,152 |
| 2024-09-30 | FMR, LLC | 4% | 2,429,973 | $219,523,751 |
| 2024-09-30 | Invesco Ltd. | 3% | 2,140,665 | $193,387,668 |
| 2024-09-30 | Geode Capital Management, LLC | 2% | 1,683,500 | $152,087,383 |
| 2024-09-30 | Westfield Capital Management Co LP | 2% | 1,518,465 | $137,178,122 |
| 2024-12-31 | Reinhart Partners, LLC | 2% | 1,366,873 | $123,483,301 |
For these reasons, we consider that the Lantheus is the subject of mixed market sentiment.
